Stock Price & Analysis

The S1 support level for VERA Stock is $28.19 ,The R1 resistant level for VERA Stock is $38.06.

As of the end of day on 2025-02-18, the price of VERA Stock was $27.79.

The target price for VERA Stock according to analyst rating is 64.63, with the highest price target at 77.00 and the lowest at 49.00. Analysts have a Strong Buy rating on VERA Stock overall.

The market cap of VERA is $1.8B.

Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its product candidate, atacicept, is a self-administered fusion protein that blocks both a B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) which stimulates B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. The Company is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplants. The Company is conducting a randomized, double-blind, placebo-controlled Phase 3 clinical trial in IgAN, which it refers to as ORIGIN 3, and completing the open label extension of its Phase 2b clinical trial in IgAN, which it refers to as ORIGIN 2b.

VERA has a total of 51 employees.